Carisma Therapeutics Inc
NASDAQ:CARM
Balance Sheet
Balance Sheet Decomposition
Carisma Therapeutics Inc
Carisma Therapeutics Inc
Balance Sheet
Carisma Therapeutics Inc
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
1
|
8
|
8
|
54
|
36
|
25
|
15
|
50
|
48
|
52
|
163
|
113
|
78
|
18
|
|
| Cash Equivalents |
1
|
8
|
8
|
54
|
36
|
25
|
15
|
50
|
48
|
52
|
163
|
113
|
78
|
18
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
54
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
25
|
1
|
0
|
3
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
1
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
6
|
11
|
19
|
21
|
3
|
3
|
|
| Total Current Assets |
1
|
8
|
8
|
54
|
36
|
26
|
15
|
52
|
54
|
63
|
206
|
189
|
80
|
24
|
|
| PP&E Net |
2
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
9
|
6
|
|
| PP&E Gross |
2
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
9
|
6
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
2
|
2
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
6
|
8
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
61
|
46
|
46
|
46
|
46
|
15
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
17
|
13
|
13
|
13
|
13
|
13
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
17
|
13
|
13
|
13
|
13
|
13
|
0
|
0
|
0
|
|
| Total Assets |
3
N/A
|
10
+252%
|
11
+18%
|
55
+391%
|
37
-33%
|
104
+183%
|
75
-28%
|
112
+49%
|
114
+3%
|
123
+7%
|
241
+96%
|
189
-21%
|
90
-53%
|
30
-66%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
1
|
1
|
2
|
3
|
1
|
2
|
1
|
1
|
2
|
3
|
3
|
1
|
4
|
2
|
|
| Accrued Liabilities |
1
|
1
|
1
|
2
|
2
|
2
|
4
|
5
|
6
|
4
|
8
|
29
|
9
|
8
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
1
|
0
|
2
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Other Current Liabilities |
0
|
0
|
1
|
1
|
0
|
1
|
0
|
0
|
0
|
11
|
0
|
0
|
2
|
5
|
|
| Total Current Liabilities |
2
|
2
|
5
|
5
|
8
|
4
|
5
|
6
|
9
|
18
|
12
|
31
|
16
|
16
|
|
| Long-Term Debt |
0
|
2
|
3
|
10
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
16
|
13
|
13
|
13
|
13
|
4
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
1
|
3
|
1
|
45
|
40
|
49
|
120
|
102
|
54
|
0
|
47
|
42
|
|
| Total Liabilities |
3
N/A
|
4
+36%
|
9
+134%
|
18
+104%
|
18
-2%
|
65
+265%
|
57
-13%
|
67
+18%
|
141
+109%
|
132
-6%
|
69
-48%
|
31
-55%
|
63
+103%
|
58
-7%
|
|
| Equity | |||||||||||||||
| Common Stock |
20
|
45
|
57
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
20
|
40
|
58
|
92
|
125
|
123
|
152
|
186
|
294
|
316
|
316
|
336
|
245
|
306
|
|
| Additional Paid In Capital |
0
|
0
|
3
|
129
|
144
|
162
|
170
|
230
|
267
|
307
|
488
|
495
|
272
|
278
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Equity |
0
N/A
|
6
N/A
|
2
-60%
|
37
+1 500%
|
19
-49%
|
39
+105%
|
18
-53%
|
44
+146%
|
27
N/A
|
9
+66%
|
172
N/A
|
158
-8%
|
27
-83%
|
28
N/A
|
|
| Total Liabilities & Equity |
3
N/A
|
10
+252%
|
11
+18%
|
55
+391%
|
37
-33%
|
104
+183%
|
75
-28%
|
112
+49%
|
114
+3%
|
123
+7%
|
241
+96%
|
189
-21%
|
90
-53%
|
30
-66%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
1
|
1
|
1
|
2
|
4
|
5
|
7
|
10
|
10
|
41
|
42
|
|
| Preferred Shares Outstanding |
0
|
45
|
53
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|